Comment on Drug pricing reform could be huge for big pharma — here is who has the most to lose

Drug pricing reform could be huge for big pharma — here is who has the most to lose

It has been a rough few months for pharmaceutical and healthcare companies. The overnight price hike of Daraprim, a drug to treat AIDs, cancer, and malaria, by a biotech company led by Martin Shkreli in mid-September garnered public outrage and political backlash. Presidential candidate Hillary Clinton later described the move as 'outrategous', and the Democratic members of the House Oversight Committee have subsequently requested a hearing regarding the outsized price hikes.

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News